ArticleProbiotics and antimicrobial proteins2026
Screening of Lipid-Lowering Acid Bacteria from Traditional Koumiss to Develop a New Probiotic Starter Culture.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
With obesity posing a growing global health burden, probiotic interventions are gaining attention as potential therapeutic strategies. This study moves beyond conventional single-strain approaches by developing a rationally designed multi-strain consortium sourced from the under-explored microbial niche of traditional koumiss. Sixteen lactic acid bacterial strains were isolated and screened using key in vitro lipid-lowering indicators. Two high‑performing strains, Lactobacillus plantarum SR6 and Enterococcus faecalis SM5, were selected and formulated into a 1:1 composite (SR6‑SM5). The composite not only exhibited synergistically enhanced functional properties-including strong gastrointestinal tolerance, with a survival rate of over 95.7% in gastric juice and over 76% in intestinal juice, high adhesion potential (hydrophobicity 93.00 ± 0.25%; auto-aggregation 90.58 ± 0.31%), notable antioxidant activity (ABTS
Indexed as
Identifiers
41697618What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.